Pfizer acquired Metsera after a bidding war with Novo Nordisk.
1 report, 1 independent
Updated Aug 4
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer acquired Metsera after a bidding war with Novo Nordisk.
Who's involved
What this event is mainly aboutKeep exploring
Part of
The weight loss drug market is dominated by major players like Pfizer, Viking Therapeutics, Eli Lilly, and Novo Nordisk, with potential M&A activity and public commentary.Also in this story
- Major pharmaceutical companies, including Viking Therapeutics, Eli Lilly, and Novo Nordisk, are advancing their weight loss drug pipelines.
- Viking Therapeutics' drug results were less favorable than Eli Lilly's, leading to speculation that Viking may seek a partnership or acquisition.
- Partnership between Novo Nordisk and Hims & Hers Health terminated due to unauthorized drug promotion in the GLP-1 weight loss market.
- Institutional investor Stanley Druckenmiller's firm must file Form 13F with the SEC regarding its new position in Viking Therapeutics, amidst market competition among weight loss drug companies.
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Novo Nordisk
Danish pharmaceutical company
Related events
- A representative made specific stock market transactions on September 19, 2026, involving Novo Nordisk, PepsiCo, and JPMorgan Chase & Co.
- Novo Nordisk leadership undergoes changes amidst intensifying competition in the GLP-1 market, involving companies like Eli Lilly and Orion.
- Eli Lilly captured market share from Novo Nordisk in the weight loss drug sector.